Design and Synthesis of Non-Covalent Imidazo[1,2-<i>a</i>]quinoxaline-Based Inhibitors of EGFR and Their Anti-Cancer Assessment.

Kumar, Manvendra; Joshi, Gaurav; Arora, Sahil; Singh, Tashvinder; Biswas, Sajal; Sharma, Nisha; Bhat, Zahid Rafiq; Tikoo, Kulbhushan; Singh, Sandeep; Kumar, Raj

Design and Synthesis of Non-Covalent Imidazo[1,2-a]quinoxaline-Based Inhibitors of EGFR and Their Anti-Cancer Assessment.

Kumar, Manvendra; Joshi, Gaurav; Arora, Sahil; Singh, Tashvinder; Biswas, Sajal; Sharma, Nisha; Bhat, Zahid Rafiq; Tikoo, Kulbhushan; Singh, Sandeep; Kumar, Raj.

Afiliação

Kumar M; Laboratory for Drug Design and Synthesis, Department of Pharmaceutical Sciences and Natural Products, School of Health Sciences, Central University of Punjab, Bathinda 151401, Punjab, India.
Joshi G; Laboratory for Drug Design and Synthesis, Department of Pharmaceutical Sciences and Natural Products, School of Health Sciences, Central University of Punjab, Bathinda 151401, Punjab, India.
Arora S; School of Pharmacy, Graphic Era Hill University, Dehradun 248171, Uttarakhand, India.
Singh T; Laboratory for Drug Design and Synthesis, Department of Pharmaceutical Sciences and Natural Products, School of Health Sciences, Central University of Punjab, Bathinda 151401, Punjab, India.
Biswas S; Department of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda 151401, Punjab, India.
Sharma N; Laboratory for Drug Design and Synthesis, Department of Pharmaceutical Sciences and Natural Products, School of Health Sciences, Central University of Punjab, Bathinda 151401, Punjab, India.
Bhat ZR; Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, S.A.S. Nagar 160062, Punjab, India.
Tikoo K; Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, S.A.S. Nagar 160062, Punjab, India.
Singh S; Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, S.A.S. Nagar 160062, Punjab, India.
Kumar R; Department of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda 151401, Punjab, India.

Molecules ; 26(5)2021 Mar 09.

Article em En | MEDLINE | ID: mdl-33803355

Assuntos

Receptores ErbB/antagonistas & inibidores; Quinoxalinas/química; Quinoxalinas/farmacologia; Células A549; Antineoplásicos/farmacologia; Carcinoma Pulmonar de Células não Pequenas/metabolismo; Linhagem Celular Tumoral; Proliferação de Células/efeitos dos fármacos; Resistencia a Medicamentos Antineoplásicos/efeitos dos fármacos; Ensaios de Seleção de Medicamentos Antitumorais; Receptores ErbB/metabolismo; Cloridrato de Erlotinib/farmacologia; Gefitinibe/farmacologia; Humanos; Imidazóis/química; Imidazóis/farmacologia; Concentração Inibidora 50; Neoplasias Pulmonares/metabolismo; Simulação de Acoplamento Molecular; Mutação/efeitos dos fármacos; Inibidores de Proteínas Quinases/farmacologia; Relação Estrutura-Atividade

Palavras-chave

anticancer agents; imidazo[1,2-a]quinoxaline; mutant EGFR inhibitors; non-covalent EGFR inhibitors

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quinoxalinas / Receptores ErbB Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quinoxalinas / Receptores ErbB Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article